Literature DB >> 17623254

Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.

Antonia Dimitrakopoulou-Strauss1, Martin Hoffmann, Raoul Bergner, Michael Uppenkamp, Michael Eisenhut, Leyun Pan, Uwe Haberkorn, Ludwig G Strauss.   

Abstract

INTRODUCTION: Dynamic positron emission tomography (PET) studies with 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) were performed in patients with advanced nonsmall cell lung cancer (NSCLC) who received palliative chemotherapy to evaluate the impact of full kinetic analysis and assess its value with regard to short or long survival.
MATERIALS AND METHODS: The evaluation includes 42 metastatic lesions in 14 patients with NSCLC. All patients received a combined chemotherapeutic protocol consisting of vinorelbin and oxaliplatin. The survival data served as reference for the PET data. All patients were examined before onset of chemotherapy and on day 15-21 after onset of the first cycle. The following parameters were retrieved from the dynamic PET studies: standardized uptake value (SUV), fractal dimension, two-compartment model with computation of k1, k2, k3, k4 (unit: 1/min), the fractional blood volume, and the FDG-influx according to Patlak was calculated using the formula (k1 x k3) / (k2 + k3). We used a two-group classification, namely, a short- and long-term survival group based on the median survival time (193 days) as a cutoff. A support vector machines (SVM) analysis was used for classification of the two a prior defined groups.
RESULTS: The observed survival times varied from 40 to 392 days with a median survival time of 193 days. Most kinetic parameters demonstrated only small changes mostly declining after one cycle. The change in all kinetic parameters did not correlate to the survival-based classification. The change in SUV was significant between the first and second study (p = 0.006) but without an impact on the prediction of short or long survival. SVM-based analysis revealed the highest correct classification rate (CCR) between short and long survival for the combination of SUV and influx of the first study and SUV, influx, k2, and k4 of the second study with a CCR of 95.2%.
CONCLUSION: The results demonstrate that a full kinetic analysis of the FDG kinetics in NSCLC is helpful for the classification into short or long survival and may be used to identify those patients who may benefit from this palliative chemotherapeutic protocol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623254     DOI: 10.1007/s11307-007-0103-6

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  16 in total

1.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation.

Authors:  K Mikolajczyk; M Szabatin; P Rudnicki; M Grodzki; C Burger
Journal:  Med Inform (Lond)       Date:  1998 Jul-Sep

2.  Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.

Authors:  Nanette M T Freedman; Senthil K Sundaram; Karen Kurdziel; Jorge A Carrasquillo; Millie Whatley; Joann M Carson; David Sellers; Steven K Libutti; James C Yang; Stephen L Bacharach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-23       Impact factor: 9.236

3.  Requirements and implementation of a flexible kinetic modeling tool.

Authors:  C Burger; A Buck
Journal:  J Nucl Med       Date:  1997-11       Impact factor: 10.057

4.  Dynamic 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography of liver tumours without blood sampling.

Authors:  S Keiding; O L Munk; K M Schiøtt; S B Hansen
Journal:  Eur J Nucl Med       Date:  2000-04

Review 5.  The applications of PET in clinical oncology.

Authors:  L G Strauss; P S Conti
Journal:  J Nucl Med       Date:  1991-04       Impact factor: 10.057

6.  PET-FDG as predictor of therapy response in patients with colorectal carcinoma.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; J Rudi
Journal:  Q J Nucl Med       Date:  2003-03

7.  Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer.

Authors:  Olivier Couturier; Guy Jerusalem; Jean-Michel N'Guyen; Roland Hustinx
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

8.  Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig Strauss
Journal:  Hell J Nucl Med       Date:  2006 Jan-Apr       Impact factor: 1.102

9.  Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Cyrill Burger; Anne Rühl; Gisela Irngartinger; Wolfgang Stremmel; Jochen Rudi
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

Review 10.  Chemotherapeutic management of stage IV non-small cell lung cancer.

Authors:  Mark A Socinski; David E Morris; Gregory A Masters; Rogerio Lilenbaum
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more
  15 in total

1.  Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Gerlinde Egerer; Julie Vasamiliette; Thomas Schmitt; Uwe Haberkorn; Bernd Kasper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

Review 2.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

3.  (18)F-Deoxyglucose (FDG) kinetics evaluated by a non-compartment model based on a linear regression function using a computer based simulation: correlation with the parameters of the two-tissue compartment model.

Authors:  Ludwig G Strauss; Leyun Pan; Caixia Cheng; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

4.  Noise considerations for PET quantification using maximum and peak standardized uptake value.

Authors:  Martin A Lodge; Muhammad A Chaudhry; Richard L Wahl
Journal:  J Nucl Med       Date:  2012-05-24       Impact factor: 10.057

5.  Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients.

Authors:  Angelo Castello; Carlo Russo; Fabio Grizzi; Dorina Qehajaj; Egesta Lopci
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 6.  Lung cancer-a fractal viewpoint.

Authors:  Frances E Lennon; Gianguido C Cianci; Nicole A Cipriani; Thomas A Hensing; Hannah J Zhang; Chin-Tu Chen; Septimiu D Murgu; Everett E Vokes; Michael W Vannier; Ravi Salgia
Journal:  Nat Rev Clin Oncol       Date:  2015-07-14       Impact factor: 66.675

7.  Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.

Authors:  Dimitris J Apostolopoulos; Antonia Dimitrakopoulou-Strauss; Peter Hohenberger; Safwan Roumia; Ludwig G Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-12       Impact factor: 9.236

8.  A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.

Authors:  Paul Flechsig; Clemens Kratochwil; Arne Warth; Daniel Rath; Viktoria Eichwald; Peter E Huber; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

9.  [PET-CT for nuclear medicine diagnostics of multiple myeloma].

Authors:  A Dimitrakopoulou-Strauss
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

Review 10.  Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients.

Authors:  Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ludwig G Strauss
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.